Table 3 Biomarkers over the first 4 weeks on ART by randomised enhanced prophylaxis vs cotrimoxazole only
From: Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa
Variable | Enhanced prophylaxis – mean (+/−SD)b | Cotrimoxazole prophylaxis only – mean (+/−SD)b | Interaction p-valuea | ||
|---|---|---|---|---|---|
Week 0 | Week 4 | Week 0 | Week 4 | ||
Plasma biomarkers | |||||
sCD14 (ng/ml) | 3523 (2010–6175) | 3756 (2133–6612) | 3558 (2081–6084) | 3614 (2059–6344) | 0.67 |
sCD163 (ng/ml) | 935 (403–1688) | 956 (406–1738) | 871 (346–1636) | 908 (346–1737) | 0.57 |
CRP (mg/l) | 2 (1–4) | 3 (2–4) | 2 (1–4) | 3 (2–4) | 0.84 |
D-dimer (ng/ml) | 3414 (1422–8197) | 3286 (1402–7701) | 3383 (1259–9089) | 3317 (1280–8601) | 0.65 |
Eotaxin | 69 (29–163) | 61 (26–144) | 68 (29–155) | 59 (26–137) | 0.14 |
GM-CSF | 48 (18–128) | 45 (17–118) | 49 (18–133) | 48 (18–126) | 0.78 |
GROA | 67 (16–282) | 64 (15–276) | 66 (15–293) | 62 (14–272) | 0.43 |
I-FABP | 2098 (892–4933) | 3433 (1682–7006) | 1807 (792–4124) | 2964 (1408–6236) | 0.002 |
IFNα | 1.6 (0.4–6.3) | 0.8 (0.3–2.1) | 1.6 (0.4–6.4) | 0.7 (0.3–1.9) | 0.49 |
IFNγ | 193 (75–494) | 149 (54–413) | 183 (69–481) | 161 (58–444) | 0.67 |
IL-10 | 12 (3–41) | 11 (3–42) | 11 (3–40) | 11 (3–41) | 0.98 |
IL-12p70 | 20 (10–41) | 19 (10–38) | 20 (10–41) | 20 (10–39) | 0.41 |
IL-13 | 11 (5–26) | 11 (5–25) | 11 (5–27) | 11 (5–26) | 0.92 |
IL-15 | 7 (2–28) | 7 (2–26) | 7 (2–28) | 7 (2–27) | 0.45 |
IL-17A | 16 (7–37) | 15 (6–36) | 15 (6–36) | 15 (6–34) | 0.46 |
IL-18 | 210 (82–538) | 162 (60–441) | 197 (76–507) | 172 (63–470) | 0.73 |
IL-1α | 1.27 (0.41–3.94) | 1.23 (0.40–3.82) | 1.32 (0.41–4.30) | 1.24 (0.40–3.79) | 0.76 |
IL-1β | 46 (14–147) | 42 (13–136) | 42 (13–139) | 42 (14–132) | 0.83 |
IL-1RA | 220 (31–1532) | 140 (23–864) | 218 (30–1587) | 159 (24–1067) | 0.90 |
IL-2 | 35 (19–65) | 33 (18–60) | 33 (18–62) | 33 (18–61) | 0.75 |
IL-21 | 135 (36–504) | 129 (35–474) | 139 (37–527) | 141 (38–523) | 0.98 |
IL-22 | 167 (47–596) | 155 (44–548) | 164 (45–603) | 162 (46–573) | 0.69 |
IL-23 | 421 (96–1839) | 422 (96–1855) | 421 (89–2003) | 456 (106–1963) | 0.79 |
IL-27 | 106 (28–399) | 99 (27–368) | 100 (26–387) | 102 (27–389) | 0.74 |
IL-31 | 44 (7–274) | 36 (6–211) | 43 (7–265) | 38 (7–219) | 0.89 |
IL-4 | 45 (10–203) | 42 (10–181) | 48 (11–209) | 47 (11–196) | 0.84 |
IL-5 | 60 (24–149) | 52 (21–129) | 57 (24–137) | 54 (23–129) | 0.59 |
IL-6 | 96 (33–273) | 85 (29–248) | 95 (32–281) | 89 (30–267) | 0.48 |
IL-7 | 3.7 (1.1–12.6) | 3.0 (0.9–10.3) | 3.5 (1.0–12.2) | 2.8 (0.8–9.3) | 0.40 |
IL-8 | 60 (13–273) | 47 (10–235) | 60 (12–285) | 50 (10–253) | 0.48 |
IL-9 | 118 (24–586) | 107 (21–538) | 123 (24–635) | 124 (25–620) | 0.66 |
IP10 | 604 (177–2065) | 423 (116–1544) | 623 (193–2014) | 438 (123–1556) | 0.80 |
LBP (mg/l) | 26 (17–39) | 23 (14–38) | 27 (17–44) | 24 (14–41) | 0.95 |
MCP1 | 96 (43–369) | 77 (35–286) | 100 (46–364) | 76 (36–248) | 0.06 |
MIP1α | 13 (3–46) | 12 (3–45) | 12 (3–45) | 11 (3–40) | 0.06 |
MIP1β | 140 (40–491) | 140 (41–479) | 134 (37–480) | 129 (38–438) | 0.20 |
RANTES | 450 (136–1482) | 461 (138–1543) | 469 (149–1475) | 440 (142–1367) | 0.24 |
SDF1A | 939 (292–3021) | 883 (278–2801) | 957 (290–3157) | 857 (269–2728) | 0.29 |
sST2 | 14181 (5400–37238) | 11927 (4604–30898) | 15250 (5423–42888) | 13441 (4612–39170) | 0.68 |
TNFα | 65 (29–145) | 58 (27–128) | 60 (28–130) | 58 (27–127) | 0.75 |
TNFβ | 29 (5–164) | 28 (5–156) | 34 (5–225) | 32 (5–193) | 0.53 |
Stool biomarkers | |||||
A1AT (mg/l) | 259 (100–673) | 200 (80–496) | 268 (100–718) | 262 (114–599) | 0.01 |
MPO (ng/ml) | 2168 (804–5843) | 1258 (590–2683) | 2056 (760–5560) | 1664 (652–4248) | 0.005 |
NEO (nmol/l) | 270 (60–1216) | 569 (136–2376) | 350 (76–1614) | 664 (159–2770) | 0.86 |
